Rifaximina [Spanish]

Rifaximina [Spanish] Brand names, Rifaximina [Spanish] Analogs

Rifaximina [Spanish] Brand Names Mixture

Sans-Acne Solution (Alcohol Anhydrous + Erythromycin)
Staticin Lot (Alcohol Anhydrous + Erythromycin + Laureth 4)
T-Stat Lot (Alcohol Anhydrous + Erythromycin)
T-Stat Pad-Lot (Alcohol Anhydrous + Erythromycin)

Rifaximina [Spanish] Chemical_Formula

C₁₂H₂₀N₂O₃S

Rifaximina [Spanish] RX_link

http://www.rxlist.com/cgi/generic/betapaceaf.htm

Rifaximina [Spanish] fda sheet

Rifaximina_[Spanish] FDA

Rifaximina [Spanish] msds (material safety sheet)

Rifaximina [Spanish] Synthesis Reference

No information avaliable

Rifaximina [Spanish] Molecular Weight

272.365 g/mol

Rifaximina [Spanish] Melting Point

206.5-207 ^oC

Rifaximina [Spanish] H₂O Solubility

Soluble (5510 mg/L)

Rifaximina [Spanish] State

Solid

Rifaximina [Spanish] LogP

2.382

Rifaximina [Spanish] Dosage Forms

Tablets (white, capsule-shaped, for oral administration)

Rifaximina [Spanish] Indication

For the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.

Rifaximina [Spanish] Pharmacology

Sotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.

Rifaximina [Spanish] Absorption

In healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.

Rifaximina [Spanish] side effects and Toxicity

The most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.

Rifaximina [Spanish] Patient Information

Rifaximina [Spanish] Organisms Affected

Humans and other mammals